Use of immunesuppressant receptor

Abstract

The present invention relates to use of an antagonist of BIR1 (B cell immunoglobulin receptor 1) related to the present invention, a method for screening the antagonist, in addition to subtype polypeptides of BIR1, the polynucleotide encoding them and antibodies for the polypeptides. BIR1 functions as an immunosuppressive receptor, and the antagonist of BIR1 has immunopotentive activity, which is able to use for preventing and/or treating a cancer, an immunodeficiency disease or an infectious disease.

1 - 19 . (canceled) 
     
     
         20 . A method of suppressing an immune response, comprising administering to a subject in need thereof an effective amount of an antibody that cross-links a protein having the amino acid sequence set forth in any one of SEQ ID NOs: 1 to 6 with CD14/TLR4 complex. 
     
     
         21 . The method of  claim 20 , wherein the antibody cross-links a protein having the amino acid sequence set forth in any one of SEQ ID NOs: 1 to 6 with TLR4. 
     
     
         22 . The method of  claim 20 , wherein the antibody cross-links a protein having the amino acid sequence set forth in any one of SEQ ID NOs: 1 to 4 with TLR4. 
     
     
         23 . The method of  claim 20 , wherein the subject is a patent with autoimmune disease, rejection reaction after organ transplantation, or inflammatory disease. 
     
     
         24 . The method of  claim 23 , wherein the autoimmune disease is selected from the group consisting of arthritis, autoimmune hepatitis, autoimmune glomerulonephritis, autoimmune insulitis, autoimmune orchitis, autoimmune oophoritis, ulcerative colitis, Sjogren's syndrome, Crohn disease, Behcet disease, Wegner granulomatosis, hypersensitivity angiitis, periarteritis nodosa, Hashimoto disease, myxoedema, Basedow disease, Addison disease, autoimmune hemolytic anemia, sudden thrombopenia, pernicious anemia, myasthenia gravis, demyelinating disease, aortitis syndrome, psoriasis, pemphigus, pemphigoid, collagen disease, Guillain-Barre syndrome, polyglandular autoimmune syndrome type II, primary biliary cirrhosis, vitiligo vulgaris, type I diabetes mellitus, systemic lupus erythematosus, arterial thrombosis, venous thrombosis, habitual abortion, thrombopenia and anti-phospholipid antibody syndrome. 
     
     
         25 . The method of  claim 23 , wherein the rejection reaction after organ transplantation is a rejection reaction after renal transplantation, liver transplantation, heart transplantation and/or lung transplantation, a rejection reaction by bone marrow transplantation or graft versus host disease. 
     
     
         26 . The method of  claim 23 , wherein the inflammatory disease is selected from the group consisting of dermatitis, colitis, Takayasu arteritis, giant cell arteritis, polyarteritis nodosa, Wegener granuromatosis, Churg-Strauss syndrome, allergic skin angiitis, Henoch-Schonlein purpura, hypersensitivity angiitis, angiitis syndrome, thromboangiitis obliterans, nodular vasculitis, arthritis, chronic rheumatoid arthritis, rheumatoid arthritis, osteoarthritis, tuberculous arthritis, suppurative arthritis, psoriatic arthritis, internal derangement of knee joint, idiopathic osteonecrosis, osteoarthritis, viral hepatitis, autoimmune hepatitis, acute nephritis, chronic glomerulonephritis, rapidly progressive nephritic syndrome, acute glomerulonephritis after hemolytic streptococcal infection, membranoproliferative glomerulonephritis, Goodpasture syndrome, mesangial proliferative glomerulonephritis, interstitial nephritis, acute infectious gastritis, allergic gastritis, chronic gastritis, pancreatitis, enteritis, laryngitis and neuritis.